Omalizumab as a Succesfull Therapy in Normocomplementemic Urticarial Vasculitis: A Series of Four Patients and Review of the Literature

• Published in: Annals of dermatology Vol. 31; no. 3; pp. 335 - 338
• Main Authors: Degirmentepe, Ece Nur, Kızıltac, Kubra, Etikan, Pırıl, Singer, Ralfi, Memet, Bachar, Kocaturk, Emek
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Dermatological Association; The Korean Society for Investigative Dermatology 01-06-2019; 대한피부과학회
• Subjects: Case Report; 피부과학; Omalizumab; Urticarial vasculitis
• ISSN: 1013-9087; 2005-3894
• DOI: 10.5021/ad.2019.31.3.335

Urticarial vasculitis is an eruption characterized by inflamed itchy or painful red papules or plaques that resemble urticaria but last longer than 24 hours and heal with residual pigmentation or purpura. Histopathologically, urticarial vasculitis presents as leukocytoclastic vasculitis with perivascular infiltrate and fibrin deposits. The treatment options are oral antihistamines, oral corticosteroids, dapsone, colchicine and hydroxychloroquine. We report four cases with normocomplementemic urticarial vasculitis who were treated with omalizumab and a brief review of the literature on the use of omalizumab in normocomplementemic urticarial vasculitis.